AZ505: A Potent and Selective SMYD2 Inhibitor for Epigenetic and Cancer Research

Executive Summary: AZ505 is a potent and selective small molecule inhibitor of the protein lysine methyltransferase SMYD2, exhibiting an IC50 of 0.12 μM and a Ki of 0.3 μM in enzymatic assays (Chen et al., 2023). It acts as a substrate-competitive inhibitor by binding to the peptide substrate groove of SMYD2 without competing with the cofactor SAM. AZ505 shows >600-fold selectivity over related methyltransferases, including SMYD3, DOT1L, and EZH2 (APExBIO). AZ505 is widely used to dissect the role of SMYD2 in epigenetic regulation, cancer biology, and renal fibrosis models. Proper solubilization and storage are essential for reproducible results. This article synthesizes peer-reviewed evidence and practical guidance for deploying AZ505 in advanced research workflows.

Biological Rationale

SMYD2 (SET and MYND domain-containing 2) is a protein lysine methyltransferase implicated in the methylation of both histone and non-histone substrates. Its enzymatic activity regulates transcription, cell proliferation, and DNA damage responses (Chen et al., 2023). Overexpression of SMYD2 has been documented in multiple cancers, including gastric cancer and esophageal squamous cell carcinoma (ESCC), where it promotes tumorigenesis and alters epigenetic landscapes [contrast: This article extends mechanistic details beyond the overview in TCS359.com]. In chronic kidney disease (CKD), SMYD2-mediated methylation events contribute to pathological fibrosis by modulating transcription of pro-fibrotic genes via histone H3K36 methylation and non-histone substrates such as p53 and Rb. Targeting SMYD2 with selective inhibitors like AZ505 enables the investigation of these pathways and the evaluation of therapeutic hypotheses in disease models.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a small molecule, substrate-competitive inhibitor of SMYD2 developed to block the methylation of lysine residues on histones (notably H3 and H4) and non-histone proteins. The compound binds to the peptide substrate binding groove of SMYD2, hindering substrate access while not interfering with the binding of S-adenosylmethionine (SAM), the methyl donor [APExBIO, B1255 datasheet]. This mode of inhibition is critical for selectivity, as it exploits structural differences between SMYD2 and other lysine methyltransferases. AZ505 does not significantly inhibit SMYD3, DOT1L, or EZH2 at concentrations up to 83.3 μM. This selectivity minimizes off-target activity and enables precise dissection of SMYD2-specific biological functions in experimental systems. The compound is soluble in DMSO, with optimal dissolution achieved by warming to 37°C and applying ultrasonic agitation.

Evidence & Benchmarks

• AZ505 inhibits SMYD2 enzymatic activity with an IC50 of 0.12 μM and a Ki of 0.3 μM in cell-free assays (Chen et al., 2023).
• In selectivity panels, AZ505 shows minimal inhibition (<5%) of SMYD3, DOT1L, and EZH2 at concentrations ≤ 10 μM (APExBIO).
• In a cisplatin-induced chronic kidney disease (CKD) mouse model, AZ505 reduced renal fibrosis, suppressed expression of pro-fibrotic markers, and inhibited epithelial-mesenchymal transition (EMT) (Chen et al., 2023).
• AZ505 treatment decreased phosphorylation of Smad3 and STAT3, while increasing renal protective factor Smad7 in vivo (Figure 4, Chen et al., 2023).
• In cancer cell models, AZ505 has been used to study the epigenetic regulation of tumor suppressors, including p53 and Rb, through inhibition of lysine methylation ([contrast: This article clarifies selectivity and mechanistic data beyond KDM2A.com]).

Applications, Limits & Misconceptions

AZ505 is primarily intended for scientific research use in the following domains:

• Epigenetic regulation research: Dissecting the role of SMYD2-mediated methylation events in gene regulation, chromatin remodeling, and signal transduction.
• Cancer biology research: Investigating SMYD2’s contribution to tumorigenesis, including in gastric cancer and ESCC models with SMYD2 overexpression.
• Renal fibrosis and CKD models: Evaluating the therapeutic impact of SMYD2 inhibition on renal injury, fibrosis, and inflammatory signaling pathways.
• Protein lysine methyltransferase inhibition studies: Benchmarking selectivity and pathway specificity among histone-modifying enzymes.

Related work on substrate-competitive SMYD2 inhibition and translational disease models is reviewed in Strategic Horizons in Epigenetic Regulation [contrast: The present article updates therapeutic context and in vivo evidence from 2023 CKD studies].

Common Pitfalls or Misconceptions

• AZ505 is not suitable for diagnostic or clinical therapeutic use; it is for research use only (APExBIO).
• It does not inhibit all lysine methyltransferases; activity is highly selective for SMYD2 and negligible for SMYD3, DOT1L, or EZH2 at recommended concentrations.
• Improper solubilization (cold DMSO, lack of agitation) may lead to incomplete dissolution and assay variability.
• Effects observed in CKD or cancer models may not generalize to all disease contexts; validation is needed for each biological system.
• AZ505’s mechanism is substrate-competitive—not a SAM-competitive or irreversible inhibitor—which may influence assay design and interpretation.

Workflow Integration & Parameters

For optimal results, AZ505 (SKU B1255, APExBIO) should be dissolved in DMSO, with heating to 37°C and ultrasonic shaking to ensure full solubilization. Stock solutions are stable at -20°C for extended periods. Recommended working concentrations for cell-based assays range from 0.1–5 μM, depending on the model and endpoint. For solution preparation and handling, refer to the product page. Protocols should include vehicle controls and, where possible, parallel testing with structurally distinct SMYD2 inhibitors. Data interpretation should consider the substrate-competitive nature of inhibition and potential compensatory upregulation of related enzymes.

For advanced workflow guidance and troubleshooting, see AZ505, a Potent and Selective SMYD2 Inhibitor: Scenario-Based Guidance [contrast: The present article provides direct links to primary evidence and quantitative benchmarks].

Conclusion & Outlook

AZ505 is a rigorously characterized, potent, and selective tool compound for SMYD2 inhibition in epigenetic and cancer research. Its substrate-competitive mechanism, high selectivity, and reproducible activity in disease models make it a valuable asset for dissecting histone methylation pathways. Ongoing research is expanding its application in models of fibrosis, cancer, and other conditions where SMYD2 is dysregulated. As with all research-use-only reagents, proper experimental controls and validation remain essential for translational relevance. For ordering and full technical details, refer to the APExBIO AZ505 product page.